Amphastar Pharmaceuticals Revenue 2012-2026 | AMPH
Amphastar Pharmaceuticals revenue from 2012 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
|
Amphastar Pharmaceuticals Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $720 |
| 2024 | $732 |
| 2023 | $644 |
| 2022 | $499 |
| 2021 | $438 |
| 2020 | $350 |
| 2019 | $322 |
| 2018 | $295 |
| 2017 | $240 |
| 2016 | $255 |
| 2015 | $252 |
| 2014 | $210 |
| 2013 | $230 |
| 2012 | $204 |
| 2011 | $118 |
|
Amphastar Pharmaceuticals Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2026-06-30 | $184 |
| 2026-03-31 | $171 |
| 2025-12-31 | $183 |
| 2025-09-30 | $192 |
| 2025-06-30 | $174 |
| 2025-03-31 | $171 |
| 2024-12-31 | $187 |
| 2024-09-30 | $191 |
| 2024-06-30 | $182 |
| 2024-03-31 | $172 |
| 2023-12-31 | $178 |
| 2023-09-30 | $181 |
| 2023-06-30 | $146 |
| 2023-03-31 | $140 |
| 2022-12-31 | $135 |
| 2022-09-30 | $120 |
| 2022-06-30 | $123 |
| 2022-03-31 | $120 |
| 2021-12-31 | $121 |
| 2021-09-30 | $112 |
| 2021-06-30 | $102 |
| 2021-03-31 | $103 |
| 2020-12-31 | $96 |
| 2020-09-30 | $83 |
| 2020-06-30 | $86 |
| 2020-03-31 | $85 |
| 2019-12-31 | $83 |
| 2019-09-30 | $80 |
| 2019-06-30 | $79 |
| 2019-03-31 | $80 |
| 2018-12-31 | $90 |
| 2018-09-30 | $76 |
| 2018-06-30 | $71 |
| 2018-03-31 | $58 |
| 2017-12-31 | $60 |
| 2017-09-30 | $58 |
| 2017-06-30 | $65 |
| 2017-03-31 | $57 |
| 2016-12-31 | $64 |
| 2016-09-30 | $64 |
| 2016-06-30 | $68 |
| 2016-03-31 | $59 |
| 2015-12-31 | $77 |
| 2015-09-30 | $64 |
| 2015-06-30 | $54 |
| 2015-03-31 | $57 |
| 2014-12-31 | $56 |
| 2014-09-30 | $60 |
| 2014-06-30 | $49 |
| 2014-03-31 | $46 |
| 2013-12-31 | $55 |
| 2013-09-30 | $59 |
| 2013-06-30 | $63 |
| 2013-03-31 | $53 |
| 2012-12-31 | $52 |
| 2012-09-30 | $57 |
| 2012-06-30 | $49 |
| 2012-03-31 | $46 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.019B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |